Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q1 FY2023 Earnings Presentation
24 slides from Lincoln Pharmaceuticals's earnings presentation, 2022
Slide 1: Q1 FY2023 Earnings Presentation
Q1 FY2023 Earnings Presentation GROWING IS COMMITMENT. WE POSSESS. P H A R M A C E U T IC A L S LT D . H E ALTH C A R E F O R A L L www.lincolnpharma.com 1
Slide 2: Safe Harbor
Safe Harbor This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfo
Slide 3: Corporate Overview
CORPORATE OVERVIEW BACKGROUND PRODUCT PORTFOLIO MANUFACTURING EXPORTS • Established in the year 1979, • 1700 registered products and • Manufacturing facility at • Exports increased to 56% in Lincoln Pharma has developed another 700 in pipeline Khatraj in Ahmedabad and FY22 from 11% in FY13. 600 plus
Slide 4: Q1FY23 Business Performance & Future Roadmap
Q1FY23 Business Performance & Future Roadmap • Company has reported Net Profit of Rs. 15.01 crore, EBITDA of Rs. 23.41 crore and Total income of Rs. 129.97 crore for the Q1FY23. Company continuous to remain 'Net Debt Free' after multiple expansion & acquisition of Cephalosporin plant. • Company has
Slide 5: Q1FY23 Standalone Results
Q1FY23 Standalone Results NET REVENUE EBITDA NET PROFIT 130.0 124.2 27.3 17.7 104.4 23.4 15.0 19.3 11.0 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Q1 FY2023 Earnings Presentation Fig (Rs. Cr) 5
Slide 6: Performance – Focused Therapeutic Areas
Performance – Focused Therapeutic Areas Revenue Breakup 4% 2% 3% 2% General Anti Infectives 29.4% 22.5% 9% 26.3% 24% Therapeutic Area 24.4% Respiratory Systems 14% Alimentary Tract and Metabolism Genito Urinary System and Sex Hormones Q1 FY23 8.4% Q1 FY22 5.2% 13% 15% Musculo-Skeletal System 3.4% 14
Slide 7: Performance Overview
Performance Overview Standalone Financial Performance (Rs. Cr) Q1 Q4 Full Year Y-o-Y Particulars FY2022 FY2023 FY2022 FY2021 FY2022 Growth (%) Net Revenue 124.2 130.0 104.4 428.7 482.1 12.5% EBITDA 27.3 23.4 19.3 92.8 105.5 13.7% Margin (%) 22.0% 18.0% 18.5% 21.6% 21.9% Profit Before Tax 25.0 20.9 1
Slide 8: About - Lincoln Pharmaceuticals Ltd
About - Lincoln Pharmaceuticals Ltd Providing Affordable and Innovative medicines for healthier lives. VISION To spark a universal attempt to uncover cures of diseases by focused and targeted R&D, through forging Strategic alliances both domestically and internationally. MISSION • Focused on deliver
Slide 9: Key Milestones
Key Milestones 1979 1984-85 2000 1996-97 Lincoln was incorporated & Received WHO – GMP for plant / Domestic Market Expansion; commences operations as a Launched IPO & Listed on BSE production unit Covered 80% of India Market Partnership Firm 2015-16 2016-17 2010-11 2017-18 Listed on NSE Launched 3 p
Slide 10: Growth Drivers – Ready for the Next Big Leap
Growth Drivers – Ready for the Next Big Leap • Company has completed expansion for launching Cephalosporin products at Mehsana, Gujarat. Invested Rs. 30 crore in the facility including capacity expansion. CAPEX • Company continuous to remain 'Net Debt Free' after multiple expansion & acquisition of
Slide 11: Lincoln Pharmaceuticals Ltd - Financial Overview
Lincoln Pharmaceuticals Ltd - Financial Overview Year Revenue EBITDA Net Profit EPS ROCE Share Price FY 22 472.1 105.5 69.4 34.6 21.9% 311 FY 12 175.5 16.9 5.1 3.1 10.0% 25.5 10 Yrs CAGR 10.4% 20.1% 30.0% 27.1% 1190 bps 28.4% Book Value (Per Share) Market Cap (Rs. Cr) Net Debt (Rs. Cr) 216 623 188 1
Slide 12: Business Revenue Mix
Business Revenue Mix Particular (Rs. cr) FY 2013 (%) FY 2017 (%) FY 2022 (%) Domestic Sales 145.03 74.5% 246.46 67.4% 205.90 43.6% Exports 49.67 25.5% 119.27 32.6% 266.18 56.4% FY13 FY17 FY22 25.5% 32.6% 43.6% 56.4% 67.4% 74.5% Exports Domestic Exports Domestic Exports Domestic Q1 FY2023 Earnings Pr
Slide 13: Global Footprint
Global Footprint Presence over 60 + Countries in Europe, Latin America, Africa, Asia Pacific, South East Asia and 26 States across India Europe: France South & Central Africa: Angola, Benin, Botswana, Asia : Afghanistan, Armenia, America : Bolivia, Burkina Faso, Burundi, Cameroon, Azerbaijan, Bhutan
Slide 14: Research & Development
Research & Development NDDS Formulations Introduced as First Time in India ▪ Anti-fungal vaginal spray ▪ Diclofenac rectal spray ▪ Sildenafil oral spray ▪ Ondansetron Hydrochloride Oral Spray (DOMI-UP) ▪ Paracetamol 1000mg Programmed Release Tablet (PA-12) ▪ Micronized Progesterone Vaginal Spray (PR
Slide 15: Innovations - Lincoln Pharma
Innovations - Lincoln Pharma Q1 FY2023 Earnings Presentation 15
Slide 16: New Launches – Domestic Market
New Launches – Domestic Market Q1 FY2023 Earnings Presentation 16
Slide 17: New Launches – International Market
New Launches – International Market Q1 FY2023 Earnings Presentation 17
Slide 18: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Gyneacological Sterile Ophthalmic Dermatologist Gastro Intestinal Anti Allergic / Anti- Eye Preparation Products Range asthmatics Drops/Ointment Anti-bacterial / Vitamins / Minerals Analgesic / Anti- Anti-malarial Anti-viral/ Anti- Otology / Anti-
Slide 19: Best in Class Facilities
Best in Class Facilities Certifications: EU-GMP, TGA, WHO-GMP Certified; ISO 9001:2015 Certified. R&D Center: Approved by Government of India; Team of 30 plus scientists for R&D. Green Energy: Windmill project and 1MW Solar Roof installed. Producing 65% of company’s total energy consumption. Dosage
Slide 20: Best in Class Facilities
Best in Class Facilities Certifications: WHO-GMP Certified; ISO 9001:2015 Certified. R&D Center: Approved Team of 10 plus scientists for R&D. Dosage Forms Produced at Unit 3 OSD and DRY POWDER INJECTION Description Annual Capacity Unit Description Size Annual Capacity Unit Tablet (Compression & Coat
Slide 21: Financial Highlights
Financial Highlights (Rs. Cr) Total Revenue Net Profit 482.1 428.7 69.4 396.3 62.3 51.5 FY20 FY21 FY22 FY20 FY21 FY22 EBITDA Net Worth 105.5 432.9 92.8 366.4 76.5 304.1 FY20 FY21 FY22 FY20 FY21 FY22 Q1 FY2023 Earnings Presentation 21
Slide 22: Profitability Ratios
Profitability Ratios EBITDA Margin PAT Margin 21.7% 21.9% 14.5% 14.4% 19.3% 13.0% FY20 FY21 FY22 FY20 FY21 FY22 ROCE RONW 22.0% 22.6% 21.9% 16.9% 17.0% 16.0% FY20 FY21 FY22 FY20 FY21 FY22 Q1 FY2023 Earnings Presentation 22
Slide 23: Shareholding Information
Shareholding Information June 2022 March 2022 Investor Category No. of No. of Shares % Holding No. of No. of Shares % Holding Shareholders Held Shareholders Held Promoter Group 29 88,29,612 44.08% 29 84,22,173 42.05% Public Holding 31,873 1,12,00,116 55.92% 32,418 1,16,07,555 57.95% Total 31,902 2,0
Slide 24: Corporate Office
CORPORATE OFFICE LINCOLN HOUSE B/h, Satyam Complex, Science City Road, Sola, Ahmedabad – 380 060, Gujarat, INDIA Phone: +91-79-41078000 Fax: +91-79-41078062 E-mail: info@lincolnpharma.com Web: www.lincolnpharma.com CIN: L24230GJ1995PLC024288 Darshit A. Shah Gopal Modi CFO, Lincoln Pharmaceuticals Lt
Lincoln Pharmaceuticals — Q1 FY2023 Earnings Presentation on 6ix